Central Serous Chorioretinopathy

How it works

Risks & contraindications

Other

Highlighted claims

• Central serous chorioretinopathy is a macular disease involving serous fluid accumulation beneath the neurosensory retina. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
• CSC commonly causes central scotoma, metamorphopsia, and micropsia. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
• CSC predominantly affects middle-aged men in high-stress occupations. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
• Chronic CSC can cause irreversible retinal pigment epithelium damage. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
• A long-term observational study found that 12.8% of chronic CSC patients became legally blind over a mean follow-up of 11.3 years. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
• The pathophysiology of CSC involves choroidal hyperpermeability. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial
• CSC can progress to pachychoroid neovascularisation. — Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trial